PhII ICb With/Without Erbitux in MBC Pts (CA225200)
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Sponsor: Bristol-Myers Squibb
A PHASE2 clinical study on Metastatic Breast Cancer, this trial is ongoing. The trial is conducted by Bristol-Myers Squibb and has accumulated 14 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Pfizer
- US Oncology Research
For direct contact, visit the study record on ClinicalTrials.gov .